Company intelligence / Profile preview

Freedom Bio Pharma

Tiburon/San Francisco, California, United Statesin.linkedin.com ↗

Ownership: Private
Development stage: Other

Overview

The lead program, FREE001 ("extended efficacy" ketamine), demonstrated in a Yale PoC study a duration of antidepressant effect lasting up to three times longer than standard ketamine/esketamine treatments. Phase IIa trial with n=120 underway in mid-2024. Multiple additional programs are at preclinical or early clinical stages.[5][8]

Therapeutic areas: Psychiatry
Modalities: Small molecules (notably ketamine and combination therapies)[1][6]
Industry: Biotech

Beyond the preview

Go deeper on Freedom Bio Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Freedom Bio Pharma.

Explore the full profile